12.1 C
New Delhi
Friday, January 21, 2022

Molnupiravir and Paxlovid , the heavily promoted antiviral drug ,Are they really safe ?

Most Popular

So many new drugs come to the market and marketed as the panacea for the illness.
History reveals many such drugs had to be withdrawn due to toxicity.

If you have practiced medicine in the last 2 to 3 decades will remember many drugs that were withdrawn due to severe adverse effects.

Cisapride was used for heartburn,flatulence got withdrawn in 2003,it was shown to cause heart rhythm disturbances

Rofecoxib was a drug prescribed right and left for arthritic pain but later shown causing more heart attacks and thus withdrawn from the market.

This drug was marketed by Merck the same company promoting Molnupiravir the anti COVID pill which has been flagged up with problems specially to pregnant women and those planning to get pregnant

Terfenadine was used for allergy drug.It was withdrawn

Rosiglitazone an anti diabetic drug had 13,000 law suits as it was shown to cause more heart attacks.

When the modern Allopathy looks at Ayurveda as herbal medicine field,the reality is long list of medicines that were used heavily in allopathy but got withdrawn due to toxicities.

Why this post now?

Molnupiravir and Paxlovid two antiviral drugs promoted heavily for the COVID but we have to be cautious that no drug is safer and doctors should exercise caution in not going overboard to prescribe to everybody( an Indian phenomenon).

Want to express your thoughts, write for us contact number: +91-8779240037

Disclaimer The author is solely responsible for the views expressed in this article. The author carry the responsibility for citing and/or licensing of images utilized within the text. The opinions, facts and any media content in them are presented solely by the authors, and neither Trunicle.com nor its partners assume any responsibility for them. Please contact us in case of abuse at Trunicle[At]gmail.com

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest article